从瘫痪到行走：严重视神经脊髓炎谱系障碍复发时的自体造血干细胞移植后骨髓移植
Plegia to walking: AHSCBMT in severe NMOSD relapse.
作者信息
Carlisle Nicola, Hari Parameswaran, Brod Staley
机构信息
Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
出版信息
BMJ Neurol Open. 2020 Oct 26;2(2):e000073. doi: 10.1136/bmjno-2020-000073. eCollection 2020.
Abstract
OBJECTIVES
Neuromyelitis optica is a devastating, relapsing, inflammatory, autoimmune disorder characterised in large part by attacks of optic neuritis and transverse myelitis causing blindness and plegia in many patients. Eighty-three per cent of patients with transverse myelitic attacks and 67% of patients with optic neuritis attacks have no or a partial recovery.
METHODS
Results from The European Group for Blood and Marrow Transplantation Autoimmune Diseases Working Party imply failure of autologous haematopoietic stem cell bone marrow transplantation.
RESULTS AND CONCLUSION
We present a case that despite eventual relapse, made a remarkable functional recovery after bone marrow transplantation which may justify bone marrow transplantation in severe cases.
摘要
目的
视神经脊髓炎是一种严重的、复发性的、炎症性自身免疫性疾病，其主要特征是视神经炎和横贯性脊髓炎发作，导致许多患者失明和瘫痪。83%发生横贯性脊髓炎发作的患者和67%发生视神经炎发作的患者未恢复或仅部分恢复。
方法
欧洲血液和骨髓移植学会自身免疫性疾病工作组的结果表明自体造血干细胞骨髓移植失败。
结果与结论
我们报告一例病例，该病例尽管最终复发，但在骨髓移植后功能恢复显著，这可能说明在严重病例中行骨髓移植是合理的。
相似文献
1
Plegia to walking: AHSCBMT in severe NMOSD relapse.
BMJ Neurol Open. 2020 Oct 26;2(2):e000073. doi: 10.1136/bmjno-2020-000073. eCollection 2020.
2
Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects.
Mult Scler Relat Disord. 2020 Nov;46:102538. doi: 10.1016/j.msard.2020.102538. Epub 2020 Oct 7.
3
Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation.
Front Neurol. 2020 Jun 16;11:537. doi: 10.3389/fneur.2020.00537. eCollection 2020.
4
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
J Neuroinflammation. 2016 Sep 27;13(1):280. doi: 10.1186/s12974-016-0718-0.
5
Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice.
Neurol Ther. 2021 Dec;10(2):767-783. doi: 10.1007/s40120-021-00253-4. Epub 2021 May 27.
6
Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders.
AJNR Am J Neuroradiol. 2017 May;38(5):949-953. doi: 10.3174/ajnr.A5141. Epub 2017 Mar 16.
7
[Transverse myelitis syndrom as a result of neuromyelitis optica spectrum disorders, systemic lupus erythematosus and myasthenia gravis combination].
Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(7. Vyp. 2):97-106. doi: 10.17116/jnevro202012007297.
8
Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature.
Mult Scler Relat Disord. 2017 Apr;13:93-97. doi: 10.1016/j.msard.2017.02.015. Epub 2017 Feb 20.
9
Cortical blindness and not optic neuritis as a cause of vision loss in a Sjögren's syndrome (SS) patient with the neuromyelitis optica spectrum disorder (NMOSD): Challenges of ascribing demyelinating syndromes to SS: a case report.
Medicine (Baltimore). 2017 Aug;96(34):e7454. doi: 10.1097/MD.0000000000007454.
10
Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders.
Mult Scler Relat Disord. 2020 Jun;41:102045. doi: 10.1016/j.msard.2020.102045. Epub 2020 Mar 6.
引用本文的文献
1
Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications.
Cells. 2022 Jul 11;11(14):2165. doi: 10.3390/cells11142165.
本文引用的文献
1
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
N Engl J Med. 2019 Nov 28;381(22):2114-2124. doi: 10.1056/NEJMoa1901747.
2
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5.
3
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
N Engl J Med. 2019 Aug 15;381(7):614-625. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3.
4
Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.
Mult Scler Relat Disord. 2019 Feb;28:64-68. doi: 10.1016/j.msard.2018.12.011. Epub 2018 Dec 9.
5
Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark.
Neurology. 2018 Dec 11;91(24):e2265-e2275. doi: 10.1212/WNL.0000000000006645. Epub 2018 Nov 9.
6
Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant.
Front Immunol. 2018 Mar 12;9:410. doi: 10.3389/fimmu.2018.00410. eCollection 2018.
7
Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party.
Mult Scler. 2015 Feb;21(2):189-97. doi: 10.1177/1352458514541978. Epub 2014 Jul 30.
8
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
Brain. 2012 Jun;135(Pt 6):1834-49. doi: 10.1093/brain/aws109. Epub 2012 May 9.
9
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.
J Neuroinflammation. 2012 Jan 19;9:14. doi: 10.1186/1742-2094-9-14.
10
Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.
Bone Marrow Transplant. 2010 Jun;45(6):1014-21. doi: 10.1038/bmt.2009.305. Epub 2009 Oct 26.
Zotero 插件